Evidence map›Paper›PMID 33435570›Full record

ArticleVaccines2021

Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity.

Marie-Eve Laliberté-Gagné, Marilène Bolduc, Caroline Garneau, Santa-Mariela Olivera-Ugarte, Pierre Savard, Denis Leclerc

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marie-Eve Laliberté-GagnéDepartment of Microbiology, Infectiology and Immunology, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.
Marilène BolducDepartment of Microbiology, Infectiology and Immunology, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.
Caroline GarneauDepartment of Microbiology, Infectiology and Immunology, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.
Santa-Mariela Olivera-UgarteDepartment of Microbiology, Infectiology and Immunology, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.ORCID 0000-0002-1229-8399
Pierre SavardDepartment of Molecular biology, medical biochemistry and pathology, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.
Denis LeclercDepartment of Microbiology, Infectiology and Immunology, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.ORCID 0000-0002-9323-1638
Université Laval · CA

Funding

Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada RGPIN-2016-05852CIHR 298143
6 · The paper itself

Abstract

backgroundThe papaya mosaic virus (PapMV) vaccine platform is a rod-shaped nanoparticle made of the recombinant PapMV coat protein (CP) self-assembled around a noncoding single-stranded RNA (ssRNA) template. The PapMV nanoparticle induces innate immunity through stimulation of the Toll-like receptors (TLR) 7 and 8. The display of the vaccine antigen at the surface of the nanoparticle, associated with the co-stimulation signal via TLR7/8, ensures a strong stimulation of the immune response, which is ideal for the development of candidate vaccines. In this study, we assess the impact of where the peptide antigen is fused, whether at the surface or at the extremities of the nanoparticles, on the immune response directed to that antigen.

methodsTwo different peptides from influenza A virus were used as model antigens. The conserved M2e peptide, derived from the matrix protein 2 was chosen as the B-cell epitope, and a peptide derived from the nucleocapsid was chosen as the cytotoxic T lymphocytes (CTL) epitope. These peptides were coupled at two different positions on the PapMV CP, the N- (PapMV-N) or the C-terminus (PapMV-C), using the transpeptidase activity of Sortase A (SrtA). The immune responses, both humoral and CD8+ T-cell-mediated, directed to the peptide antigens in the two different fusion contexts were analyzed and compared. The impact of coupling density at the surface of the nanoparticle was also investigated.

conclusionsThe results demonstrate that coupling of the peptide antigens at the N-terminus (PapMV-N) of the PapMV CP led to an enhanced immune response to the coupled peptide antigens as compared to coupling to the C-terminus. The difference between the two vaccine platforms is linked to the enhanced capacity of the PapMV-N vaccine platform to stimulate TLR7/8. We also demonstrated that the strength of the immune response increases with the density of coupling at the surface of the nanoparticles.

Indexed as

influenza M2einfluenza nucleocapsidpapaya mosaic virus (PapMV)rod-shaped nanoparticlesortase (SrtA)vaccine platform

Identifiers

PMID33435570
PMCPMC7829862
OpenAlexW3112835911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.